Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2020 Nov 1.

Published in final edited form as: Free Radic Biol Med. 2019 Jul 26;143:25–46. doi: 10.1016/j.freeradbiomed.2019.07.024

Figure 7. — HBMECs were transfected with ATF3-T4 or ATF3-T5 siRNA for 18 h and treated with TGRL lipolysis products (TL) for 3 h. Cell lysates were analyzed by western blotting. A) Both transcript variants significantly suppressed lipolysis-induced ATF3; B) Inhibiting with ATF3-T5 siRNA decreased lipolysis-induced JunB, but not with ATF3-T4 siRNA; C) inhibiting with ATF3-T4 siRNA or ATF3-T5 siRNA further increased lipolysis-induced p-c-Jun expression; D) Inhibiting with ATF3-T4 siRNA further increased lipolysis-induced JDP2, but not with ATF3-T5; E) Inhibiting with ATF3-T4 siRNA further increased CHAC1, but not with ATF3-T5 siRNA; F) Inhibiting with ATF3-T4 siRNA or ATF3-T5 siRNA further significantly increased lipolysis-induced ATF4; G) inhibiting with ATF3-T4 siRNA significantly decreased lipolysis-induced DR5, but not with ATF3-T5 siRNA; H) inhibiting with ATF3-T4 siRNA or ATF3-T5 siRNA further increased TNFR1; I) inhibiting with ATF3-T4 siRNA or ATF3-T5 siRNA decreased lipolysis-induced NRF2; J) Inhibiting with ATF3-T4 siRNA or ATF3-T5 siRNA suppressed lipolysis-induced eIF2α; K) Inhibiting with ATF3-T4 siRNA or ATF3-T5 siRNA suppressed lipolysis-induced COX-2; L) Inhibiting with ATF3-T4 siRNA suppressed lipolysis-induced cleaved capase-9, but further increased ATF3-T5 siRNA; M) Inhibiting with ATF3-T5 siRNA suppressed lipolysis-induced PARP, but no change with ATF3-T4 siRNA; N) Both transcript variants suppressed lipolysis-activated active caspase-3; O) Inhibiting with ATF3-T4 siRNA further increased p53, but suppressed with ATF3-T5 siRNA. N = 3/treatment group.

Figure 7. — HBMECs were transfected with ATF3-T4 or ATF3-T5 siRNA for 18 h and treated with TGRL lipolysis products (TL) for 3 h. Cell lysates were analyzed by western blotting. A) Both transcript variants significantly suppressed lipolysis-induced ATF3; B) Inhibiting with ATF3-T5 siRNA decreased lipolysis-induced JunB, but not with ATF3-T4 siRNA; C) inhibiting with ATF3-T4 siRNA or ATF3-T5 siRNA further increased lipolysis-induced p-c-Jun expression; D) Inhibiting with ATF3-T4 siRNA further increased lipolysis-induced JDP2, but not with ATF3-T5; E) Inhibiting with ATF3-T4 siRNA further increased CHAC1, but not with ATF3-T5 siRNA; F) Inhibiting with ATF3-T4 siRNA or ATF3-T5 siRNA further significantly increased lipolysis-induced ATF4; G) inhibiting with ATF3-T4 siRNA significantly decreased lipolysis-induced DR5, but not with ATF3-T5 siRNA; H) inhibiting with ATF3-T4 siRNA or ATF3-T5 siRNA further increased TNFR1; I) inhibiting with ATF3-T4 siRNA or ATF3-T5 siRNA decreased lipolysis-induced NRF2; J) Inhibiting with ATF3-T4 siRNA or ATF3-T5 siRNA suppressed lipolysis-induced eIF2α; K) Inhibiting with ATF3-T4 siRNA or ATF3-T5 siRNA suppressed lipolysis-induced COX-2; L) Inhibiting with ATF3-T4 siRNA suppressed lipolysis-induced cleaved capase-9, but further increased ATF3-T5 siRNA; M) Inhibiting with ATF3-T5 siRNA suppressed lipolysis-induced PARP, but no change with ATF3-T4 siRNA; N) Both transcript variants suppressed lipolysis-activated active caspase-3; O) Inhibiting with ATF3-T4 siRNA further increased p53, but suppressed with ATF3-T5 siRNA. N = 3/treatment group.